Searched for
INSULIN ANALOGUES
Mankind Pharma inks in-licensing pact with China's Chongqing Chenan BiopharmaceuticalMankind Pharma has secured an exclusive agreement with Chongqing Chenan Biopharmaceutical. This partnership focuses on commercialising two ...- Weight loss secret? Woman reveals 5 foods she avoided to lose 32 kgBy cutting out five pivotal food items, Deepti shed an impressive thirty-two kilograms. She made a significant switch from sugary drinks to...
- Novo Nordisk readies once-a-week insulin shot for Indian marketNovo Nordisk is set to introduce Awiqli, an innovative once-weekly insulin, in India shortly. This remarkable treatment drastically cuts do...
- Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-ShawBiocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...
- Biocon shares surge 3% as subsidiary obtains USFDA approval for diabetes drugBiocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This...
- Eris Lifesciences jumps 10% as investors cheer JV with MJ BiopharmThe JV, dubbed Eris Biopharm, would be in the ratio of 70:30, with Eris holding a 70 per cent stake.
- Eris enters JV with MJ Pharma to commercialise insulins in domestic marketThe business of the joint venture will be kickstarted with the launch of human insulin in the fourth quarter of FY22.
- Novo Nordisk launches diabetes drug Ryzodeg in IndiaNovo Nordisk launched it's combination diabetic drug Ryzodeg, priced at Rs 1,595 for 300 units, for people with type II diabetes in India.
- Lupin inks pact with South Korean firm to launch diabetes drugAs per the strategic distribution pact inked between the two companies, Mumbai-based Lupin will launch LG Life Sciences' Insulin Glargine.
- Our Malaysia facility is focussed on insulin & insulin analogues: Kiran Mazumdar Shaw, BioconIt is likely to take some time before we can actually start very aggressively marketing globally from the Malaysia facility.
- Bristol-Myers Squibb, Sanofi-Aventis in race for drug marketing pact with BioconA deal could include a combination of upfront payments, milestone-linked payments and royalties on sales of the product once it is develope...
- Pfizer deal shot in arm for BioconAs per the deal, Biocon will conduct clinical development and regulatory filings while Pfizer will get the exclusive rights to market these...
- 'Basalog does not come under NPPA purview, NPPA should make the correction'Biocon’s CMD Kiran Mazumdar Shaw is betting big on the oral insulin drug that the company is scheduled to unveil next March. She said the f...
- Wockhardt, Biocon insulin prices to fall by 70%Indian copycats of French drug maker Sanofi Aventis’ premium insulin formulation, Lantus, will soon become about 70% cheaper with the count...
- Wockhardt, Biocon under NPPA scannerWockhardt and Biocon have come under the drug price regulator National Pharmaceutical Pricing Authority (NPPA) scanner for allegedly violat...
- Wockhardt to foray into biosimilar marketWockhardt is planning to tap the $33-billion biosimilar market and focus on products that lose patent protection in 2013-2015.
- Wockhardt opens lower after drug launchWockhardt stock opened the day lower at Rs 94.50 on news that it has launched its new insulin (Glaritus)that has a global market of $2 bill...
- Sanofi-Aventis to shore up diabetes bizEurope’s largest pharma company Sanofi-Aventis has decided to shore up its diabetes business in India
- Danish drug co Novo Nordisk to set up data centreNovo Nordisk, a speciality pharma company with global leadership in the diabetes care market, has decided to set up its global data managem...
- India fast emerging as data management hubNovo Nordisk, a speciality pharma company with global leadership in the diabetes care market, has decided to set up its global data managem...
Load More
